GlassScriptPhysician profile
Jaymie H Pennington
NPI 1780894717
$17,439.49
in general payments reported to CMS, 2019-2025
37 companies · $3,820 in 2025
The $3,820 reported for 2025 was more than what 89% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,631 · 2020: $1,229 · 2021: $2,276 · 2022: $2,568 · 2023: $2,424 · 2024: $3,492 · 2025: $3,820.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,721 · Education: $13.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,721.41 |
| Education | $13.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $6,892.86 | 2019-2025 | |
| Janssen Biotech, INC. | $2,343.04 | 2019-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $2,059.00 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $839.48 | 2019-2025 | Xifaxan, Plenvu, Relistor |
| Gilead Sciences, INC. | $809.91 | 2019-2025 | |
| Pfizer INC. | $490.32 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $409.81 | 2019-2024 | Dificid |
| Celgene Corporation | $387.44 | 2021-2023 | Zeposia |
| Phathom Pharmaceuticals, INC. | $274.49 | 2024-2025 | Voquezna |
| Nestle Healthcare Nutrition INC. | $263.04 | 2021-2023 | |
| Regeneron Healthcare Solutions, INC. | $235.54 | 2022-2025 | Dupixent |
| Aimmune Therapeutics, INC. | $231.44 | 2024-2025 | Zenpep |
| Medtronic, INC. | $200.53 | 2022-2025 | Dragonfly Pancreaticobiliary Scope and Instrument Channel Caps, Interstim |
| Amgen INC. | $194.85 | 2020-2023 | Avsola, Amjevita |
| Lilly USA, LLC | $190.36 | 2024-2025 | Omvoh |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $183.09 | 2021-2023 | Renflexis, Hadlima |
| Ironwood Pharmaceuticals, INC | $174.10 | 2020-2024 | Linzess |
| Genzyme Corporation | $152.51 | 2022-2023 | |
| Redhill Biopharma INC. | $149.83 | 2020-2021 | |
| Ferring Pharmaceuticals INC. | $138.74 | 2019-2025 | Clenpiq, Rebyota |
| Janssen Scientific Affairs, LLC | $104.98 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $101.77 | 2022 | |
| Qol Medical, LLC | $88.59 | 2022 | |
| Madrigal Pharmaceuticals | $88.27 | 2025 | Rezdiffra |
| Evoke Pharma, INC. | $73.98 | 2021-2022 | |
| Intercept Pharmaceuticals, INC. | $62.64 | 2019-2025 | |
| Allergan, INC. | $54.42 | 2019-2020 | |
| Braintree Laboratories, INC. | $48.26 | 2020-2023 | Suflave, Sutab |
| Micro-Tech Endoscopy USA, INC. | $47.53 | 2024-2025 | Lesionhunter, Riteclip |
| Ipsen Biopharmaceuticals, INC | $45.72 | 2025 | Iqirvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.81 | 2020-2023 | Cyltezo |
| Celltrion USA INC. | $16.61 | 2025 | Vegzelma |
| Novo Nordisk INC | $16.29 | 2025 | Wegovy |
| Shire North American Group INC | $16.00 | 2019 | |
| Ardelyx, INC. | $13.89 | 2023 | Ibsrela |
| Echosens North America, INC. | $11.35 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$38,544.33 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaymie Pennington listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.